The Utility and Efficacy of Laparoscopic Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer at a Single Institution.


Journal

Urologia internationalis
ISSN: 1423-0399
Titre abrégé: Urol Int
Pays: Switzerland
ID NLM: 0417373

Informations de publication

Date de publication:
2020
Historique:
received: 14 01 2020
accepted: 24 04 2020
pubmed: 20 6 2020
medline: 23 4 2021
entrez: 20 6 2020
Statut: ppublish

Résumé

The aim of this study was to compare the surgical and oncological outcomes and complications of laparoscopic radical cystectomy (LRC) to those of open radical cystectomy (ORC) in patients with muscle-invasive bladder cancer (MIBC). Our study focused on patients with histologically confirmed stage T2-T4a urothelial carcinoma of the bladder without distant metastases, who underwent LRC (LRC group) or ORC (ORC group). The primary endpoints in this study were the overall survival (OS) and recurrence-free survival (RFS) rates. In this study, 59 patients, 17 underwent LRC and 42 underwent ORC, were enrolled. The 2-year OS rate was 100% in the LRC group and 88.0% in the ORC group (p = 0.85). The 2-year RFS rate was 63.5% in the LRC group and 69.5% in the ORC group (p = 0.321). On multivariate analysis, the histological type, positive lymph node, and positive resection margin were significantly associated with the OS rates. This study suggested that LRC may achieve similar oncological outcomes and fewer perioperative complications and less blood loss compared to ORC. Therefore, LRC should be considered as one of the treatment options for patients with MIBC.

Sections du résumé

BACKGROUND BACKGROUND
The aim of this study was to compare the surgical and oncological outcomes and complications of laparoscopic radical cystectomy (LRC) to those of open radical cystectomy (ORC) in patients with muscle-invasive bladder cancer (MIBC).
METHODS METHODS
Our study focused on patients with histologically confirmed stage T2-T4a urothelial carcinoma of the bladder without distant metastases, who underwent LRC (LRC group) or ORC (ORC group). The primary endpoints in this study were the overall survival (OS) and recurrence-free survival (RFS) rates.
RESULTS RESULTS
In this study, 59 patients, 17 underwent LRC and 42 underwent ORC, were enrolled. The 2-year OS rate was 100% in the LRC group and 88.0% in the ORC group (p = 0.85). The 2-year RFS rate was 63.5% in the LRC group and 69.5% in the ORC group (p = 0.321). On multivariate analysis, the histological type, positive lymph node, and positive resection margin were significantly associated with the OS rates.
CONCLUSIONS CONCLUSIONS
This study suggested that LRC may achieve similar oncological outcomes and fewer perioperative complications and less blood loss compared to ORC. Therefore, LRC should be considered as one of the treatment options for patients with MIBC.

Identifiants

pubmed: 32554972
pii: 000508192
doi: 10.1159/000508192
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

573-579

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Keita Nakane (K)

Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.

Torai Enomoto (T)

Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.

Seiji Hishida (S)

Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.

Masayuki Tomioka (M)

Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.

Tomoki Taniguchi (T)

Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.

Daiki Kato (D)

Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.

Manabu Takai (M)

Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.

Koji Iinuma (K)

Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.

Yuka Muramatsu Maekawa (Y)

Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.

Kengo Horie (K)

Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.

Kosuke Mizutani (K)

Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.

Tomohiro Tsuchiya (T)

Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan.

Shigeaki Yokoi (S)

Department of Urology, Kizawa Memorial Hospital, Minokamo, Japan.

Takuya Koie (T)

Department of Urology, Gifu University Graduate School of Medicine, Gifu, Japan, goodwin@gifu-u.ac.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH